Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The event, scheduled for September 16 at 8:30 a.m. EDT, will be webcast live, with a replay available on the company's investor relations website. The full press release can be accessed at https://ibn.fm/r0jfC.
The invitation to present at a major healthcare conference underscores growing investor interest in Helus Pharma's novel approach to mental health treatment. The company, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing proprietary novel serotonergic agonists (NSAs) – synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions.
Helus Pharma's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. This designation is significant because it is intended to expedite the development and review of drugs that may offer substantial improvement over existing therapies. The company is also developing HLP004, another proprietary NSA, in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.
The fireside chat provides an opportunity for Halstead to discuss the company's progress and vision with a broad audience of institutional investors, analysts, and healthcare experts. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that could provide durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland, positioning it to potentially address mental health markets across multiple regions.
For investors, the presentation at the Morgan Stanley conference may serve as a catalyst for increased visibility and credibility. Participation in such a prominent event often signals a company's readiness to engage with the investment community and can lead to greater analyst coverage and investor interest. The live webcast and subsequent replay also allow a wider audience to access the information, potentially broadening the company's shareholder base.
Helus Pharma's focus on serotonergic agonists places it at the forefront of a new wave of mental health treatments that seek to harness the brain's neuroplasticity. If successful, these therapies could offer new hope for patients who have not responded to traditional antidepressants. The company's pipeline, with one asset in Phase 3 and another in Phase 2, demonstrates a commitment to advancing science and addressing critical unmet needs.
For ongoing updates and more information about Helus Pharma, visit www.helus.com or follow the team on social media. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP.
